Research and Markets: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2012
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130205:nBw055827a DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/cvh6jj/juvenile_macular) has announced the addition of Global Markets Direct's new report "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease). Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Juvenile Macular Degeneration (Stargardt Disease). - A review of the Juvenile Macular Degeneration (Stargardt Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Juvenile Macular Degeneration (Stargardt Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) pipeline depth and focus of Indication therapeutics. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. For more information visit http://www.researchandmarkets.com/research/cvh6jj/juvenile_macular Source: Global Markets Direct Research and Markets Laura Wood, Senior Manager. firstname.lastname@example.org U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals Copyright Business Wire 2013
- More troops deployed in Ferguson to guard against fresh riots |
- Merkel hits diplomatic dead-end with Putin
- Jewish-nation bill frays Israel's delicate social fabric
- Ukraine reports new arrivals of Russian supplies for eastern rebels |
- Gunshots echo as violence returns to Ferguson, protests across U.S.